Gland Pharma Limited (NSE: GLAND)
India
· Delayed Price · Currency is INR | Market Cap | 289.15B |
| Revenue (ttm) | 58.90B |
| Net Income (ttm) | 6.92B |
| Shares Out | 164.75M |
| EPS (ttm) | 41.98 |
| PE Ratio | 41.81 |
| Forward PE | 31.85 |
| Dividend | 20.00 (1.14%) |
| Ex-Dividend Date | Aug 16, 2024 |
| Volume | 101,124 |
| Open | 1,787.00 |
| Previous Close | 1,787.00 |
| Day's Range | 1,748.20 - 1,804.90 |
| 52-Week Range | 1,585.70 - 2,220.95 |
| Beta | 0.30 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 4, 2024 |
About Gland Pharma
Gland Pharma Limited engages in manufacturing and sale of injectable formulations in India, the United States, Europe, Canada, Australia, New Zealand, and internationally. The company engages in research and development of pharmaceutical active pharmaceutical ingredient products, including synthesis of complex drug molecules, such as low molecular weight heparins, corticosteroids, peptides, and cytotoxic molecules. The company offers its products for various therapeutic categories, such as anti-malarial, anti-infectives, anti-neoplastic, blood ... [Read more]
Financial Performance
In 2023, Gland Pharma's revenue was 56.65 billion, an increase of 56.29% compared to the previous year's 36.25 billion. Earnings were 7.72 billion, a decrease of -1.10%.
Financial StatementsNews
Gland Pharma stock jumps 10% this week after Q2 results
Gland Pharma shares surged over 10% this week following its Q2 results, despite a 16% drop in consolidated net profit. The company posted a profit of Rs 163.53 crore for the quarter ending September 3...
Gland Pharma shares surge over 12% – Know More
Gland Pharma’s stock jumped by over 12% on November 5, 2024, after the company announced its second-quarter fiscal 2025 results, which aligned with market expectations despite a year-over-year dip in ...
Gland Pharma shares jump 6% on Q2 FY25 results
Gland Pharma Ltd. shares jumped 6% in morning trade following the announcement of its second-quarter fiscal 2025 results. The company’s consolidated net profit fell 16% to Rs 163.53 crore for the quar...
Gland Pharma share price: Goldman Sachs maintains sell call on Gland Pharma with target price of Rs 1,450, sees 10% downside
Goldman Sachs (GS) has maintained its sell call on Gland Pharma, setting a target price of ₹1,450 per share, implying a potential downside of 10% from the current market price of ₹1,609. The company’s...
Gland Pharma Q2 FY25 Results: Revenue grows 2.4% YoY to Rs 1,405.83 crore; net profit falls 15.7% to Rs 163.53 crore
Gland Pharma Limited has announced its unaudited consolidated financial results for the quarter ended September 30, 2024, showing modest revenue growth but a decline in profitability. For Q2 FY2025, G...
Pharma stocks today: Gland Pharma rises 1.53%, Aurobindo Pharma up 1.38%, while Natco Pharma falls 1.40%, and Laurus Labs down 1.41%
As of 10:31 AM, the pharma sector has witnessed both gains and losses. Gland Pharma is the top gainer, rising by 1.53% to ₹1,675.40, followed by Aurobindo Pharma, up 1.38% at ₹1,493.00. Mankind Pharma...
Pharma Stocks Update: Check out how Cipla, Lupin, Abbott India, Divi’s Lab, Zydus Life, Dr Reddy’s Lab are performing today
JB Chem rises 1.91%, Biocon gains 0.87%, while Natco Pharma drops 2.65% and Gland Pharma slips 1.38% in today's trade.
Stocks Update: Phoenix Mills drops 4.77%, Gland Pharma down 3.73%, and United Spirits loses 3.61% in today’s session
In today’s trading session, several stocks experienced notable declines, with Phoenix Mills leading the downward trend. Here’s a look at the top 11 losers: Phoenix Mills Ltd: Shares dropped by 4.77%, ...
Goldman Sachs downgrades Gland Pharma to ‘Sell’, expects 19% downside
Goldman Sachs has downgraded Gland Pharma to a ‘Sell’ rating and slashed its target price to ₹1,500 from ₹1,849, citing multiple headwinds affecting the company’s profitability. The investment bank fo...